Xeris Biopharma’s (XERS) “Buy” Rating Reiterated at HC Wainwright

Xeris Biopharma (NASDAQ:XERS)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $10.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 64.55% from the stock’s previous close.

Several other research analysts have also issued reports on XERS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, January 21st. Oppenheimer restated an “outperform” rating and set a $18.00 price target on shares of Xeris Biopharma in a research note on Friday, November 7th. Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 8th. Barclays initiated coverage on shares of Xeris Biopharma in a research note on Monday, December 8th. They issued an “overweight” rating and a $9.00 target price for the company. Finally, Piper Sandler upped their price target on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $10.08.

Xeris Biopharma Stock Down 0.7%

Shares of Xeris Biopharma stock traded down $0.04 on Monday, reaching $6.08. The stock had a trading volume of 2,360,539 shares, compared to its average volume of 1,991,403. The stock has a market capitalization of $1.01 billion, a P/E ratio of -61.31 and a beta of 0.52. The company has a 50 day moving average price of $7.23 and a 200 day moving average price of $7.64. Xeris Biopharma has a 1 year low of $3.59 and a 1 year high of $10.08.

Insider Buying and Selling at Xeris Biopharma

In other news, insider Beth Hecht sold 16,667 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $7.43, for a total value of $123,835.81. Following the completion of the transaction, the insider owned 1,308,103 shares of the company’s stock, valued at $9,719,205.29. The trade was a 1.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director John Johnson sold 135,400 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $7.22, for a total value of $977,588.00. Following the sale, the director directly owned 698,083 shares in the company, valued at approximately $5,040,159.26. This trade represents a 16.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 223,641 shares of company stock worth $1,628,285. Insiders own 6.47% of the company’s stock.

Hedge Funds Weigh In On Xeris Biopharma

Several institutional investors have recently made changes to their positions in XERS. Cetera Investment Advisers raised its holdings in Xeris Biopharma by 3.9% in the 2nd quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock valued at $216,000 after acquiring an additional 1,735 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Xeris Biopharma by 29.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after buying an additional 1,820 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Xeris Biopharma by 7.6% during the second quarter. China Universal Asset Management Co. Ltd. now owns 32,167 shares of the company’s stock worth $150,000 after buying an additional 2,264 shares during the last quarter. Royal Bank of Canada boosted its stake in Xeris Biopharma by 6.5% during the fourth quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock worth $304,000 after buying an additional 2,351 shares during the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its holdings in Xeris Biopharma by 17.7% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 16,070 shares of the company’s stock valued at $126,000 after buying an additional 2,420 shares in the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.